The remicade biosimilar market is anticipated to grow at a CAGR of 4.5% during the forecast period (2022-2028).Remicade is a branded drugapproved by theFDA which is generally taken in the form of the prescribed medication. It isa chimeric monoclonal antibodyto treat certain autoimmune diseases in adults and children. Whereas remicade biosimilar is defined as a biosimilar that belongs to the class of tumor necrosis factor blocker intended for patients with autoimmune diseases. The market growth is majorly attributed to the growing prevalence of various autoimmune disorders such as rheumatoid arthritis, plaque psoriasis, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis among others. These are conditions in which immune system mistakenly attacks the body’s own tissues or organs.
A full report of Remicade Biosimilar Market is available at:https://orionmarketreports.com/remicade-biosimilar-market-2/48410/
Further, the market growth is also attributed to the continuous focus of various prominent drug manufacturerson the development of biosimilar portfolios. They are increasingly inclined toward offering affordable biological treatment options especially in oncology. For instance, in April 2017, a biosimilar Renflexisalso known by the name as infliximab-abda, which is a tumor necrosis factor to Remicade by Samsung Bioepis and Merck & Co., was given the approval that it could be launched into the market. It was approved for almost all the indications that were approved under remicade such as plague psoriasis, ulcerative colitis, rheumatic arthritis, spinal psoriatic arthritis, and ankylosing spondylitis. Such approvals for novel biosimilar portfolios are projected to boost the growth of the global remicade biosimilar market during the forecast period.
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Indication
- Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape: Merck & Co., Inc., Pfizer Inc., and Johnson & Johnson Services, Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Remicade Biosimilars Market Report by Segment
By Indication
- Rheumatoid Arthritis
- Ulcerative Colitis
- Ankylosing Spondylitis
- Plaque Psoriasis
- Crohn’s Disease
- Psoriatic Arthritis
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
